Quick Takeaways
- Jason Hoitt has 2 issuer positions tracked on this page.
- Estimated disclosed ownership value: $337,566.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Jason Hoitt
- Location
- Bedford, MA
- Summary
- The estimated net worth of Jason Hoitt is at least $337,566 dollars as of 19 Mar 2026. Jason Hoitt is the Chief Patient Officer of Stoke Therapeutics, Inc. and owns shares of Stoke Therapeutics, Inc. (STOK) stock worth about $337.6K.
- Signature
- /s/ Jonathan Allan, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Jason Hoitt and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Stoke Therapeutics, Inc. ($337,566).
- Past-year value change for that position: -$119,311.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Jason Hoitt
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| STOK | Stoke Therapeutics, Inc. | Chief Patient Officer | $337,566 | -$119,311 | -26% | 17 Mar 2026 |
| PRVB | Provention Bio, Inc. | Chief Commercial Officer | 27 Apr 2023 |
Insider Transactions Reported by Jason Hoitt:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.